Nervous Disorder TRIZ Cases

This case shows how Sigma-1 receptor activation improves mitochondrial function, reduces ER stress, and protects neurons.

A pretreatment regimen prepares PTHS patients for fecal microbe transfer, restoring gut diversity and sustaining GI relief.

This case develops a high-sensitivity monoclonal antibody that directly inhibits ASM for neurodegenerative disease treatment and diagnosis.

This case uses GABA to activate vagal afferent nerves and regulate GLP-1 and GIP for satiety and binge eating control.

This case uses anti-Sortilin antibodies with less frequent dosing to raise CSF Progranulin and support patient compliance.

This case uses Juglans mandshurica fruit extracts to reduce infarction and support motor and cognitive recovery after stroke.

This case uses KOR ligand biomarkers to select patients for aticaprant, improving MDD symptoms and anhedonia after SSRI or SNRI failure.

This case combines traditional Chinese medicine with antiepileptic drugs to support seizure control and limit side effects.

This case uses gap-and-wing antisense design to suppress CSGalNAcT1, reduce chondroitin sulfate, and support axon regeneration.

Glyceryl tribenzoate inhalation forms slowly convert to sodium benzoate, sustaining Huntington’s therapy while reducing dosing frequency.

This case combines 5-HT6 antagonism with donepezil or memantine to address agitation, aggression, delusions, and hallucinations.

This case uses D-pinitol to stimulate ghrelin, reduce insulin resistance, and limit tau hyperphosphorylation linked to cognitive decline.

Twelve low-volume plasma exchange rounds use albumin to reduce Aβ levels and adverse effects in moderate Alzheimer’s disease.

This case uses oxygen-impermeable storage and leukoreduction to limit storage lesions while preserving blood quality for six weeks.

A cross-linked Aβ product mimics ASPD immunoreactivity, supporting stable analysis and detection without native ASPD materials.

This case uses 3.1.0 and 4.1.0 azabicycle MGL modulators to increase 2-AG and improve social novelty interest in ASD.

Micronized amine salts and proton acceptors convert the drug near skin, balancing reservoir solubility with permeability.

This case combines traditional Chinese medicine with antiepileptic drugs to maintain seizure control while reducing side effects.

Engineered DUBs restore ion channel surface expression by regulating ubiquitination in trafficking-deficient mutations.

This case uses dopamine agonist 2-aminoindan derivatives to reduce binge-session alcohol intake without promoting abstinence.

Engineered DUBs target ubiquitinated membrane proteins to restore ion channel trafficking and support mutation screening.

This case modifies aromatic structures to preserve rapid antidepressant activity while improving brain distribution and metabolic stability.

Nicotinamide riboside, pterostilbene, PDE4 inhibition, and acetylcysteine combine to improve ALS survival and motor function.

Pyridin-2(1H)one derivatives selectively inhibit p38α MAPK to reduce allodynia and hyperalgesia in chronic pain.

Formula (I) small molecules inhibit the NLRP3 inflammasome, offering an oral alternative to biologics for safety and compliance.

Explore substituted 1,2,4-triazoles that target TYK2 selectively, helping limit JAK2 effects across multiple TYK2-mediated disorders.

Selective HDAC4 compounds enhance synaptic plasticity without adverse effects.

Peripheral AAV vectors deliver therapeutic proteins to the CNS via choroid plexus cells.

A sustained-release pirfenidone matrix maintains 12-hour bioavailability for anti-fibrotic and anti-inflammatory treatment.

This case uses TREM2-targeted antibodies to modulate microglial signaling, improve amyloid uptake, and support cognitive function.

GB102, GB103, and GB104 are combined to support grip strength, muscle coordination, and intestinal flora balance.

A combined 5-HT4R agonist and ketamine composition addresses cognitive decline and perseverative behavior in Alzheimer’s disease models.

This composition uses fexofenadine to protect neurons by limiting dopaminergic cell death, inflammation, and α-synuclein aggregation.

This case uses intravenous anti-CGRP antibodies to target CGRP, addressing inadequate relief and side effects in cluster headache care.

This case uses fibroblast-derived mitochondria to replenish mitochondrial DNA and support aerobic respiration without HLA matching.

This case uses tramiprosate or 3-SPA to inhibit Aβ42 oligomers and reduce cognitive decline without antibody-driven ARIA-E risks.

This case uses a weakly basic polymer hydrogel to hold BHB, improve palatability, and support sustained ketosis without mineral overload.

This case targets TREM2 residues 19–132 to preserve surface stability, reduce shedding, and enhance phagocytosis and signaling.

This probiotic strain links GLP-1 secretion with reduced adipocyte maturation and modulation of blood glucose and lipids.

Intranasal antioxidants bypass the blood-brain barrier for CNS treatment.

Phosphate groups reduce crystallinity and improve delivery, enabling active compounds to detect amyloid beta and phosphorylated tau.

This case uses twice-daily transdermal CBD gel to reduce seizures while bypassing gastrointestinal absorption and first-pass metabolism.

Defined CDR sequences create a flexible single-domain antibody for high-affinity TREM2 targeting with lower immune heterogeneity.

Zafirlukast and related small molecules target PDI and extracellular thiol isomerases, blocking platelet aggregation and thrombus formation.

This case uses eFT508 to reverse neuropathic pain and cognitive deficits by reducing eIF4E phosphorylation.

This case combines zinc with cinnamaldehyde to activate TRPA1 at tolerable levels while supporting energy expenditure and fat oxidation.

This case combines a GUCY2C agonist with a PDE inhibitor to boost dopamine in substantia nigra cells and reduce non-specific effects.

Tailored condensed ring substituents improve D3 antagonism and D3/D2 selectivity while reducing potential side effects.

This case uses heat-treated Bifidobacterium longum and Lactobacillus rhamnosus to retain anxiety benefits in a stable postbiotic form.

Defined tetralin substituents create diverse 5-HT2A agonists for depression, substance use, and eating disorders.